Literature DB >> 22155261

Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer.

Joyce N Barlin1, Changhong Yu, Emily K Hill, Oliver Zivanovic, Valentin Kolev, Douglas A Levine, Yukio Sonoda, Nadeem R Abu-Rustum, Jae Huh, Richard R Barakat, Michael W Kattan, Dennis S Chi.   

Abstract

OBJECTIVE: To develop a nomogram based on established prognostic factors to predict the probability of 5-year disease-specific mortality after primary surgery for patients with all stages of epithelial ovarian cancer (EOC) and compare the predictive accuracy with the currently used International Federation of Gynecology and Obstetrics (FIGO) staging system.
METHODS: Using a prospectively kept database, we identified all patients with EOC who had their primary surgery at our institution between January 1996 and December 2004. Disease-specific mortality was estimated using the Kaplan-Meier method. Twenty-eight clinical and pathologic factors were analyzed. Significant factors on univariate analysis were included in the Cox proportional hazards regression model, which identified factors utilized in the nomogram. The concordance index (CI) was used as an accuracy measure, with bootstrapping to correct for optimistic bias. Calibration plots were constructed.
RESULTS: A total of 478 patients with EOC were included. The most predictive nomogram was constructed using seven variables: age, FIGO stage, residual disease status, preoperative albumin level, histology, family history suggestive of hereditary breast/ovarian cancer (HBOC) syndrome, and American Society of Anesthesiologists (ASA) status. This nomogram was internally validated using bootstrapping and shown to have excellent calibration with a bootstrap-corrected CI of 0.714. The CI for FIGO staging alone was significantly less at 0.62 (P=0.002).
CONCLUSION: We have developed an all-stage nomogram to predict 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. This tool is more accurate than FIGO staging and should be useful for patient counseling, clinical trial eligibility, postoperative management, and follow-up. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155261     DOI: 10.1016/j.ygyno.2011.12.423

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  25 in total

Review 1.  Nomograms in oncology: more than meets the eye.

Authors:  Vinod P Balachandran; Mithat Gonen; J Joshua Smith; Ronald P DeMatteo
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

2.  A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.

Authors:  Edward J Tanner; Olga T Filippova; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Oliver Zivanovic; Mary Fischer; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2018-10-16       Impact factor: 5.482

3.  Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.

Authors:  Rudy S Suidan; Mario M Leitao; Oliver Zivanovic; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Douglas A Levine; Elizabeth L Jewell; Carol L Brown; Nadeem R Abu-Rustum; Mary E Charlson; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2015-05-31       Impact factor: 5.482

4.  Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.

Authors:  Fanny Dao; Brooke A Schlappe; Jill Tseng; Jenny Lester; Alpa M Nick; Susan K Lutgendorf; Scott McMeekin; Robert L Coleman; Kathleen N Moore; Beth Y Karlan; Anil K Sood; Douglas A Levine
Journal:  Gynecol Oncol       Date:  2016-03-11       Impact factor: 5.482

5.  Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes.

Authors:  E Houben; H G M van Haalen; W Sparreboom; J A Overbeek; N P M Ezendam; J M A Pijnenborg; J L Severens; M P P van Herk-Sukel
Journal:  Med Oncol       Date:  2017-02-21       Impact factor: 3.064

6.  Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.

Authors:  Irene A Burger; Debra A Goldman; Hebert Alberto Vargas; Michael W Kattan; Changhon Yu; Lei Kou; Vaagn Andikyan; Dennis S Chi; Hedvig Hricak; Evis Sala
Journal:  Gynecol Oncol       Date:  2015-06-17       Impact factor: 5.482

7.  External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.

Authors:  Alexia Iasonos; Emily Z Keung; Oliver Zivanovic; Rosanna Mancari; Michele Peiretti; Marisa Nucci; Suzanne George; Nicoletta Colombo; Silvestro Carinelli; Martee L Hensley; Chandrajit P Raut
Journal:  Cancer       Date:  2013-03-01       Impact factor: 6.860

8.  A prognostic nomogram for prediction of recurrence in desmoid fibromatosis.

Authors:  Aimeé M Crago; Brian Denton; Sébastien Salas; Armelle Dufresne; James J Mezhir; Meera Hameed; Mithat Gonen; Samuel Singer; Murray F Brennan
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

9.  Risk-scoring model for prediction of non-home discharge in epithelial ovarian cancer patients.

Authors:  Mariam M AlHilli; Christine W Tran; Carrie L Langstraat; Janice R Martin; Amy L Weaver; Michaela E McGree; Andrea Mariani; William A Cliby; Jamie N Bakkum-Gamez
Journal:  J Am Coll Surg       Date:  2013-06-29       Impact factor: 6.113

10.  Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer.

Authors:  Ryon P Graf; Ramez Eskander; Leo Brueggeman; Dwayne G Stupack
Journal:  JAMA Netw Open       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.